Skip to content

Quantification of Cerebral Blood Flow by Arterial Spin Labeling in Vasospasm in Subarachnoid Haemorrhage

Quantification of Cerebral Blood Flow by Arterial Spin Labeling in the Screening and Monitoring of Vasospasm in Subarachnoid Haemorrhage

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02557607
Acronym
ASL-HSA
Enrollment
50
Registered
2015-09-23
Start date
2014-12-31
Completion date
2018-01-31
Last updated
2015-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid Hemorrhage

Brief summary

A technique of MRI infusion -l'Arterial Spin Labeling-, non-invasive and non-irradiating, repeatable over time, appears promising in the field. This sequence allows for routine, generate perfusion maps relating to the entire brain volume

Detailed description

The subarachnoid hemorrhage (SAH) is a relatively severe disease whose prognosis is particularly related to the early onset of arterial vasospasm, maximum between the 5th and 14th day after SAH. Many obstacles make it difficult screening and monitoring of such complication. The challenge is to be able to demonstrate a reduction in regional cerebral blood flow before the onset of irreversible parenchymal sequelae, responsible for the majority of long-term morbidity among survivors. In clinical routine, screening vasospasm is achieved by Doppler intracranial arteries (DTC). However, its sensitivity is poor with regard to the middle and anterior cerebral arteries. The gold standard for diagnosis is cerebral arteriography. However, vasospasm in arteriography or trans-cranial Doppler does not prejudice the appearance of a delayed ischemic deficit. A technique of MRI infusion -l'Arterial Spin Labeling-, non-invasive and non-irradiating, repeatable over time, appears promising in the field. This sequence allows for routine, generate perfusion maps relating to the entire brain volume

Interventions

DEVICEMRI

An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be

Sponsors

University Hospital, Angers
Lead SponsorOTHER_GOV

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults. * Who have given their written consent. * Affiliated to a social security system. * Any patient hospitalized at the University Hospital of Angers in neurosurgical intensive care unit for supervision by ASL and DTC a subarachnoid hemorrhage from all etiologies (excluding traumatic).

Exclusion criteria

* Contraindications to MRI * patient hospitalized at the University Hospital of Angers in surgical intensive care for monitoring a subarachnoid hemorrhage. * patient hospitalized at the University Hospital of Angers for monitoring a subarachnoid hemorrhage traumatic.

Design outcomes

Primary

MeasureTime frame
exploitation of raw images provided with the waning of the acquisition of the sequence ASL.15 days

Countries

France

Contacts

Primary ContactAram TER MINASSIAN, Physician
ArTerMinassian@chu-angers.fr02.41.35.52.31

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026